Virginia Cancer Specialists PC

Az itteni vizsgálatok

Miről szól a helyszín 63 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák36 vizsgálat
• Áttétes emlőrák8 vizsgálat
• Gyomor- és nyelőcsőrák7 vizsgálat
• Vastagbélrák7 vizsgálat
• Diffúz nagy B-sejtes limfóma (DLBCL)5 vizsgálat
• Máj- és epeúti rák5 vizsgálat
• Szarkóma5 vizsgálat
• Fej-nyaki daganatok4 vizsgálat
• Hasnyálmirigyrák4 vizsgálat
• Hólyagrák4 vizsgálat
• Melanóma4 vizsgálat
• Petefészekrák4 vizsgálat
• és még 14

Fázis

• 1. fázis17 vizsgálat
• 2. fázis15 vizsgálat
• 3. fázis15 vizsgálat
• 1/2. fázis10 vizsgálat
• 2/3. fázis2 vizsgálat

Állapot

• Fut, nem toboroz22 vizsgálat
• Toboroz17 vizsgálat
• Lezárult16 vizsgálat
• Leállították7 vizsgálat
• Visszavonták1 vizsgálat

Fő szponzor

• Amgen10 vizsgálat
• Pfizer7 vizsgálat
• Boehringer Ingelheim6 vizsgálat
• EMD Serono Research & Development Institute, Inc.4 vizsgálat
• Hoffmann-La Roche4 vizsgálat
• és még 24

Futó vizsgálatok

• Toboroz

  A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  NCT07365319· 2/3. fázis· Eikon Therapeutics· Forrás

  Contact: Elelta Shiferraw

• Toboroz

  Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  NCT07392892· 2/3. fázis· Pfizer· Forrás

• Toboroz

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· 3. fázis· BioNTech SE· Forrás

• Toboroz

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· 1/2. fázis· Pfizer· Forrás

• Toboroz

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· 1/2. fázis· Pfizer· Forrás

• Toboroz

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· 3. fázis· Boehringer Ingelheim· Forrás

  Contact: Boehringer Ingelheim

• Toboroz

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· 3. fázis· Pfizer· Forrás

• Toboroz

  A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  NCT07221500· 2. fázis· Nurix Therapeutics, Inc.· Forrás

• Toboroz

  A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

  NCT07140016· 1. fázis· Astellas Pharma Global Development, Inc.· Forrás

  Contact: Astellas Pharma Global Development, Inc.

• Toboroz

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· 3. fázis· Relay Therapeutics, Inc.· Forrás

  Contact: Relay Therapeutics, Inc

• Fut, nem toboroz

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· 3. fázis· Amgen· Forrás

• Fut, nem toboroz

  A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

  NCT06966453· 1/2. fázis· Pfizer· Forrás

• Toboroz

  Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  NCT06806033· 2. fázis· Hoffmann-La Roche· Forrás

• Fut, nem toboroz

  A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

  NCT06745323· 2. fázis· Amgen· Forrás

• Fut, nem toboroz

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· 3. fázis· Pfizer· Forrás

• Fut, nem toboroz

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· 2. fázis· Amgen· Forrás

• Fut, nem toboroz

  Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

  NCT06333951· 1. fázis· Amgen· Forrás

• Toboroz

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· 1/2. fázis· Boehringer Ingelheim· Forrás

  Contact: Boehringer Ingelheim

• Fut, nem toboroz

  A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

  NCT06360354· 1. fázis· Amgen· Forrás

• Toboroz

  Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

  NCT05703971· 1/2. fázis· Genprex, Inc.· Forrás

  Contact: Carrie Friedman

• Fut, nem toboroz

  Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

  NCT06117774· 3. fázis· Amgen· Forrás

• Fut, nem toboroz

  Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

  NCT06151574· 3. fázis· Boehringer Ingelheim· Forrás

• Fut, nem toboroz

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· 3. fázis· Hoffmann-La Roche· Forrás

• Fut, nem toboroz

  Study With Various Immunotherapy Treatments in Participants With Lung Cancer

  NCT05676931· 2. fázis· Gilead Sciences· Forrás

• Toboroz

  MYLUNG Consortium Part 3: Observational Study

  NCT05885698· US Oncology Research· Forrás

  Contact: Andrea Glidden, BSN, OCN

• Toboroz

  Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

  NCT04712877· Lung Cancer Mutation Consortium· Forrás

  Contact: Brian Phipps

• Toboroz

  Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

  NCT05245500· 1. fázis· Bristol-Myers Squibb· Forrás

  Contact: Alexander Spira, Site 122

• Fut, nem toboroz

  A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

  NCT05318573· 2. fázis· Fujifilm Pharmaceuticals U.S.A., Inc.· Forrás

• Fut, nem toboroz

  Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

  NCT05074810· 1/2. fázis· Verastem, Inc.· Forrás

• Fut, nem toboroz

  A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

  NCT05094336· 1/2. fázis· Amgen· Forrás

• Toboroz

  Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

  NCT04886804· 1. fázis· Boehringer Ingelheim· Forrás

  Contact: Boehringer Ingelheim

• Fut, nem toboroz

  HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

  NCT04676477· 1. fázis· Daiichi Sankyo· Forrás

• Fut, nem toboroz

  Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

  NCT04579380· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás

• Fut, nem toboroz

  MYLUNG Consortium Study Protocol 2

  NCT05644808· US Oncology Research· Forrás

• Toboroz

  Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT04221542· 1. fázis· Amgen· Forrás

• Fut, nem toboroz

  Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

  NCT04185883· 1. fázis· Amgen· Forrás

• Toboroz

  A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

  NCT03460977· 1. fázis· Pfizer· Forrás

• Fut, nem toboroz

  Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

  NCT02864992· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás

• Fut, nem toboroz

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· 2. fázis· Hoffmann-La Roche· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák7 toboroz
• Áttétes emlőrák2 toboroz
• Gyomor- és nyelőcsőrák2 toboroz
• Prosztatarák2 toboroz
• Vastagbélrák2 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Follikuláris limfóma1 toboroz
• Gyermekkori daganatok1 toboroz
• Hasnyálmirigyrák1 toboroz
• Hodgkin-limfóma1 toboroz
• Hólyagrák1 toboroz
• Krónikus limfoid leukémia (CLL)1 toboroz
• Mezotelióma1 toboroz
• Szarkóma1 toboroz
• Vesedaganat1 toboroz

Lezárt vizsgálatok

• Leállították

  Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

  NCT06939036· 1/2. fázis· Ariceum Therapeutics GmbH· Forrás

• Lezárult

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás

• Toboroz

  A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· 3. fázis· Regeneron Pharmaceuticals· Forrás

  Contact: Clinical Trials Administrator

• Lezárult

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· 3. fázis· Boehringer Ingelheim· Forrás

• Toboroz

  A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

  NCT06022029· 1. fázis· OncoNano Medicine, Inc.· Forrás

• Lezárult

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· 1/2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás

• Leállították

  A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

  NCT04999202· 1. fázis· Bayer· Forrás

• Lezárult

  Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

  NCT04813627· BioNTech SE· Forrás

• Leállították

  Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

  NCT04579757· 1/2. fázis· Hutchmed· Forrás

• Lezárult

  A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

  NCT04620330· 2. fázis· Verastem, Inc.· Forrás

• Lezárult

  A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

  NCT04539938· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás

• Lezárult

  Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

  NCT04641871· 1. fázis· Symphogen A/S· Forrás

• Lezárult

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· 3. fázis· Amgen· Forrás

• Leállították

  A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

  NCT04254107· 1. fázis· Seagen Inc.· Forrás

• Lezárult

  A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

  NCT03821233· 1. fázis· Zymeworks BC Inc.· Forrás

• Leállították

  Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

  NCT03646123· 2. fázis· Seagen Inc.· Forrás

• Leállították

  A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

  NCT03582033· 1. fázis· Seagen Inc.· Forrás

• Lezárult

  M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT03631706· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás

• Lezárult

  A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT03563716· 2. fázis· Genentech, Inc.· Forrás

• Lezárult

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· 3. fázis· Daiichi Sankyo· Forrás

• Lezárult

  A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

  NCT03468426· 1. fázis· Boehringer Ingelheim· Forrás

• Lezárult

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· 3. fázis· Hoffmann-La Roche· Forrás

• Leállították

  A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

  NCT03248492· 2. fázis· Daiichi Sankyo· Forrás

• Lezárult

  A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

  NCT02922764· 1. fázis· Inspirna, Inc.· Forrás